Press Releases

Home > Media >Press Releases

17 August 2011

Camson Biotech delivers 26% Q1 sales growth

Click here to download PDF

Camson takes right steps towards a biotech revolution

  • Camson inks technology tie-up with Wageningen University (WU) to implement develop seeds based on Cisgenic Technology
  • Camson files patent for four path-breaking biocides

Performance Highlights:

  • Camson’s Q1 net revenues grew by a robust 26% to 26.11 crore for the quarter ended June 30, 2011 from Rs. 20.71 crore for the corresponding period last year
  • EBDITA for the quarter ended grew 32% to Rs. 7.72 crore from Rs. 5.84 crore in the same quarter last fiscal.
  • Farmers realize the importance of Camson bio-products and strongly recommend them to other farmers.

Bangalore, August 17th, 2011: Camson Biotechnologies Ltd., India’s fastest growing IPR-driven biotechnology company, posted a robust 26% growth in the first quarter ended June 30, 2011 over the corresponding period the previous year. This strong growth is mainly attributed to the strong support and patronage provided by Indian farmers. The net profit increased by 29% to Rs. 6.99 crore in the first quarter ended June 30, 2011 from Rs. 5.40 crore in the same quarter last year.

This quarter saw a nation-wide acceptance among Indian farmers for Camson’s products. This is because there is now a clear understanding of the value addition Camson products provide to rural farming. The company is committed to producing zero-residue biocides and bio-fertilizers to boost agricultural practises in the country.

Technology tie-up with Wageningen University (WU)

Farmers are increasing their level of awareness and  now know the difference between seeds derived from BT technology and hybrid seeds derived from safer GMO technology such as Cisgenesis. Camson has signed a technology agreement with Netherland’s Wageningen University (WU) to develop disease-resistant and bio-friendly fruits and vegetables.

This tie-up will pave the way to garner a large share of the cash crops segment, which is pegged at Rs. 4,000 crore in the Indian market and slated to grow at 25-30% p.a. A seed derived from Cisgenic technology is considered as a safe GMO because it does not use the genes from unrelated species as in the case of a seed derived from using Transgenic technology.

Patents filed for four products

Camson has undertaken several research exercises to arrive at path-breaking biocides, which can alter the face of not just domestic but global agriculture. The company has filed for 4 patents, which is a symbol of Camson’s ability to provide the very best in technological excellence.

Commenting on the results, Dhirendra Kumar, Founder and Managing Director of Camson Biotech said: “We remain committed to farmers and our main endeavour is to provide them with eco-friendly yield. Camson’s technological tie-up with Wageningen University will pave the path for a biotech revolution within the country and abroad. We are confident of developing hybrid seeds that can be used to satisfy the hunger situation across the globe.”

About Camson Biotech

Established in 1993, Camson combines latest knowledge of breeding, molecular genetics and metagenomics in agriculture with the latest practices in environmental safety and protection to market a wide range of products that include hybrid seeds, bio-fertilizers and biocides that are non-poisonous, eco-friendly and residue-free. Headquartered in Bangalore, Camson employs the best talent in the industry to bring innovative biotechnologies to farmers. Partnering with rural farming communities, government agencies and corporate houses in India, Camson aims to empower farming communities through need-focused research and development.

For more information:

Sunil Ramakirshnan
Rigveda consulting
Tel: 09870110525

Corporate Headquarters:

Camson Bio Technologies Limited
C-7, 7th Floor, Corporate Block
GOlden Enclave Enclave, Airport Road
Bangalore - 560017
Tel: 080 40768900

R&D Center

Camson R&D
Tel:0091 080 2535 5138
Fax: 0091 080 2535 2232

< Back